Work

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Adult Subjects with NTRK Fusion-Positive Tumors.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps2599

Authors: Alexander E. Drilon, David S. Hong, Scott Cruickshank, Maegan Deegan, Nora Ku, David Michael Hyman

Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Loxo Oncology at Lilly (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2725207856

Cites:

Cited by: 3

Related to: 10